PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"33378609","Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group.","N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.","Baden LR","N Engl J Med","2021","2020/12/30","PMC7787219","","10.1056/NEJMoa2035389"
"34812653","Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA; Immune Assays Team§; Moderna, Inc. Team§; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§; United States Government (USG)/CoVPN Biostatistics Team§.","Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.","Gilbert PB","Science","2022","2021/11/23","PMC9017870","NIHMS1800809","10.1126/science.abm3425"
"34551225","Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group.","N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22.","El Sahly HM","N Engl J Med","2021","2021/09/22","PMC8482810","NIHMS1743941","10.1056/NEJMoa2113017"
"34210573","Evidence for antibody as a protective correlate for COVID-19 vaccines","Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA.","Vaccine. 2021 Jul 22;39(32):4423-4428. doi: 10.1016/j.vaccine.2021.05.063. Epub 2021 May 24.","Earle KA","Vaccine","2021","2021/07/02","PMC8142841","","10.1016/j.vaccine.2021.05.063"
"35139271","Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S","Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, Neuzil KM, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group.","N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9.","Sadoff J","N Engl J Med","2022","2022/02/09","PMC8849184","","10.1056/NEJMoa2117608"
"33761206","Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L; HVTN 702 Study Team.","N Engl J Med. 2021 Mar 25;384(12):1089-1100. doi: 10.1056/NEJMoa2031499.","Gray GE","N Engl J Med","2021","2021/03/24","PMC7888373","","10.1056/NEJMoa2031499"
"33090877","Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials","Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Juraska M, Luedtke A, Nason M, Vandebosch A, Zhou H, Cohen MS, Corey L, Hartzel J, Follmann D, Gilbert PB.","Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22.","Mehrotra DV","Ann Intern Med","2021","2020/10/22","PMC7596738","","10.7326/M20-6169"
"33730454","Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, deCamp AC, Rudnicki E, Huang Y, Gonzales P, Cabello R, Orrell C, Lama JR, Laher F, Lazarus EM, Sanchez J, Frank I, Hinojosa J, Sobieszczyk ME, Marshall KE, Mukwekwerere PG, Makhema J, Baden LR, Mullins JI, Williamson C, Hural J, McElrath MJ, Bentley C, Takuva S, Gomez Lorenzo MM, Burns DN, Espy N, Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Kublin JG, Gray G, Ledgerwood JE, Mascola JR, Cohen MS; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams.","N Engl J Med. 2021 Mar 18;384(11):1003-1014. doi: 10.1056/NEJMoa2031738.","Corey L","N Engl J Med","2021","2021/03/17","PMC8189692","NIHMS1701559","10.1056/NEJMoa2031738"
"33986625","Causal Isotonic Regression","Westling T, Gilbert P, Carone M.","J R Stat Soc Series B Stat Methodol. 2020 Jul;82(3):719-747. doi: 10.1111/rssb.12372. Epub 2020 May 13.","Westling T","J R Stat Soc Series B Stat Methodol","2020","2021/05/14","PMC8112616","NIHMS1593522","10.1111/rssb.12372"
"25985906","Reply to Dunning","Gilbert PB, Gabriel EE, Hudgens MG, Miao X, Li X, Su SC, Parrino J, Chan IS.","J Infect Dis. 2015 Nov 1;212(9):1521-3. doi: 10.1093/infdis/jiv287. Epub 2015 May 17.","Gilbert PB","J Infect Dis","2015","2015/05/20","PMC4612359","","10.1093/infdis/jiv287"
"35758878","Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk","Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Omar FL, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M, Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskine W, Dubula T, Randhawa AK, Grunenberg N, Hural J, Kee JJ, Benkeser D, Jin Y, Carpp LN, Allen M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG, Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ.","J Infect Dis. 2022 Aug 24;226(2):246-257. doi: 10.1093/infdis/jiac260.","Moodie Z","J Infect Dis","2022","2022/06/27","PMC9890908","","10.1093/infdis/jiac260"
"33077678","Prospects for a safe COVID-19 vaccine","Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A.","Sci Transl Med. 2020 Nov 4;12(568):eabe0948. doi: 10.1126/scitranslmed.abe0948. Epub 2020 Oct 19.","Haynes BF","Sci Transl Med","2020","2020/10/20","","","10.1126/scitranslmed.abe0948"
"27662407","Modeling HIV vaccine trials of the future","Gilbert PB, Huang Y, Janes HE.","Curr Opin HIV AIDS. 2016 Nov;11(6):620-627. doi: 10.1097/COH.0000000000000314.","Gilbert PB","Curr Opin HIV AIDS","2016","2016/09/24","PMC5077275","NIHMS823977","10.1097/COH.0000000000000314"
"26491081","Immune correlates of vaccine protection against HIV-1 acquisition","Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS.","Sci Transl Med. 2015 Oct 21;7(310):310rv7. doi: 10.1126/scitranslmed.aac7732.","Corey L","Sci Transl Med","2015","2015/10/23","PMC4751141","NIHMS757327","10.1126/scitranslmed.aac7732"
"26827165","Selection of HIV vaccine candidates for concurrent testing in an efficacy trial","Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.","Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29.","Huang Y","Curr Opin Virol","2016","2016/02/01","PMC4902743","NIHMS756136","10.1016/j.coviro.2016.01.007"
"23719202","Sieve analysis in HIV-1 vaccine efficacy trials","Edlefsen PT, Gilbert PB, Rolland M.","Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b.","Edlefsen PT","Curr Opin HIV AIDS","2013","2013/05/31","PMC3863593","NIHMS533774","10.1097/COH.0b013e328362db2b"
"37403227","A semiparametric Cox-Aalen transformation model with censored data","Ning X, Pan Y, Sun Y, Gilbert PB.","Biometrics. 2023 Jul 4. doi: 10.1111/biom.13895. Online ahead of print.","Ning X","Biometrics","2023","2023/07/05","","","10.1111/biom.13895"
"29948579","New approaches for censored longitudinal data in joint modelling of longitudinal and survival data, with application to HIV vaccine studies","Yu T, Wu L, Gilbert P.","Lifetime Data Anal. 2019 Apr;25(2):229-258. doi: 10.1007/s10985-018-9434-7. Epub 2018 Jun 8.","Yu T","Lifetime Data Anal","2019","2018/06/28","PMC6286694","NIHMS983553","10.1007/s10985-018-9434-7"
"29037149","chngpt: threshold regression model estimation and inference","Fong Y, Huang Y, Gilbert PB, Permar SR.","BMC Bioinformatics. 2017 Oct 16;18(1):454. doi: 10.1186/s12859-017-1863-x.","Fong Y","BMC Bioinformatics","2017","2017/10/18","PMC5644082","","10.1186/s12859-017-1863-x"
"29732896","Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa","Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE.","AIDS Res Hum Retroviruses. 2018 Aug;34(8):645-656. doi: 10.1089/AID.2018.0031. Epub 2018 Jun 19.","Janes H","AIDS Res Hum Retroviruses","2018","2018/05/08","PMC6080090","","10.1089/AID.2018.0031"
"31078451","Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials","Janes H, Donnell D, Gilbert PB, Brown ER, Nason M.","Lancet HIV. 2019 Jul;6(7):e475-e482. doi: 10.1016/S2352-3018(19)30133-X. Epub 2019 May 8.","Janes H","Lancet HIV","2019","2019/05/13","PMC6612578","NIHMS1529465","10.1016/S2352-3018(19)30133-X"
"27858965","Model-robust inference for continuous threshold regression models","Fong Y, Di C, Huang Y, Gilbert PB.","Biometrics. 2017 Jun;73(2):452-462. doi: 10.1111/biom.12623. Epub 2016 Nov 17.","Fong Y","Biometrics","2017","2016/11/19","PMC5435560","NIHMS843482","10.1111/biom.12623"
"37091190","The quest for vaccine-induced immune correlates of protection against tuberculosis","Nemes E, Fiore-Gartland A, Boggiano C, Coccia M, D'Souza P, Gilbert P, Ginsberg A, Hyrien O, Laddy D, Makar K, McElrath MJ, Ramachandra L, Schmidt AC, Shororbani S, Sunshine J, Tomaras G, Yu WH, Scriba TJ, Frahm N; BCG Correlates PIs Study Team, M72 Correlates PIs Study Team.","Vaccine Insights. 2022 Jul;1(3):165-181. doi: 10.18609/vac/2022.027. Epub 2022 Jul 29.","Nemes E","Vaccine Insights","2022","2023/04/24","PMC10117634","NIHMS1865255","10.18609/vac/2022.027"
"35995954","Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, Giorgi EE, Korber B, Edlefsen PT, Rossenkhan R, Juraska M, Rudnicki E, Kochar N, Huang Y, Carpp LN, Barouch DH, Mkhize NN, Hermanus T, Kgagudi P, Bekker V, Kaldine H, Mapengo RE, Eaton A, Domin E, West C, Feng W, Tang H, Seaton KE, Heptinstall J, Brackett C, Chiong K, Tomaras GD, Andrew P, Mayer BT, Reeves DB, Sobieszczyk ME, Garrett N, Sanchez J, Gay C, Makhema J, Williamson C, Mullins JI, Hural J, Cohen MS, Corey L, Montefiori DC, Morris L.","Nat Med. 2022 Sep;28(9):1924-1932. doi: 10.1038/s41591-022-01953-6. Epub 2022 Aug 22.","Gilbert PB","Nat Med","2022","2022/08/22","PMC9499869","","10.1038/s41591-022-01953-6"
"35353885","High Asymptomatic Carriage With the Omicron Variant in South Africa","Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, Espy N, Wallis CL, Randhawa AK, Miner MD, Ketter N, Yacovone M, Goga A, Huang Y, Hural J, Kotze P, Bekker LG, Gray GE, Corey L; Ubuntu Study Team.","Clin Infect Dis. 2022 Aug 24;75(1):e289-e292. doi: 10.1093/cid/ciac237.","Garrett N","Clin Infect Dis","2022","2022/03/30","PMC9383623","","10.1093/cid/ciac237"
"36507702","A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines","Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D.","N Engl J Med. 2022 Dec 15;387(24):2203-2206. doi: 10.1056/NEJMp2211314. Epub 2022 Dec 10.","Gilbert PB","N Engl J Med","2022","2022/12/12","","","10.1056/NEJMp2211314"
"33043428","Nonparametric variable importance assessment using machine learning techniques","Williamson BD, Gilbert PB, Carone M, Simon N.","Biometrics. 2021 Mar;77(1):9-22. doi: 10.1111/biom.13392. Epub 2020 Dec 8.","Williamson BD","Biometrics","2021","2020/10/12","PMC7946807","NIHMS1659211","10.1111/biom.13392"
"15068256","Endpoints in vaccine trials","Hudgens MG, Gilbert PB, Self SG.","Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra.","Hudgens MG","Stat Methods Med Res","2004","2004/04/08","","","10.1191/0962280204sm356ra"
"34532060","RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection","Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M.","Virus Evol. 2021 Jul 9;7(2):veab057. doi: 10.1093/ve/veab057. eCollection 2021.","Lewitus E","Virus Evol","2021","2021/09/17","PMC8438874","","10.1093/ve/veab057"
"34696352","Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission","Swan DA, Goyal A, Bracis C, Moore M, Krantz E, Brown E, Cardozo-Ojeda F, Reeves DB, Gao F, Gilbert PB, Corey L, Cohen MS, Janes H, Dimitrov D, Schiffer JT.","Viruses. 2021 Sep 24;13(10):1921. doi: 10.3390/v13101921.","Swan DA","Viruses","2021","2021/10/26","PMC8539635","","10.3390/v13101921"
"36658109","Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","Fong Y, Huang Y, Benkeser D, Carpp LN, Áñez G, Woo W, McGarry A, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team.","Nat Commun. 2023 Jan 19;14(1):331. doi: 10.1038/s41467-022-35768-3.","Fong Y","Nat Commun","2023","2023/01/19","PMC9851580","","10.1038/s41467-022-35768-3"
"21508308","HIV-1 vaccines and adaptive trial designs","Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, Fauci AS.","Sci Transl Med. 2011 Apr 20;3(79):79ps13. doi: 10.1126/scitranslmed.3001863.","Corey L","Sci Transl Med","2011","2011/04/22","PMC3616511","NIHMS455211","10.1126/scitranslmed.3001863"
"33290576","Rejoinder to ""Nonparametric variable importance assessment using machine learning techniques""","Williamson BD, Gilbert PB, Carone M, Simon N.","Biometrics. 2021 Mar;77(1):28-30. doi: 10.1111/biom.13389. Epub 2020 Dec 8.","Williamson BD","Biometrics","2021","2020/12/08","PMC8029259","NIHMS1679381","10.1111/biom.13389"
"35848843","A controlled effects approach to assessing immune correlates of protection","Gilbert PB, Fong Y, Kenny A, Carone M.","Biostatistics. 2022 Jul 15:kxac024. doi: 10.1093/biostatistics/kxac24. Online ahead of print.","Gilbert PB","Biostatistics","2022","2022/07/18","","","10.1093/biostatistics/kxac24"
"36949083","Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","Fong Y, Huang Y, Benkeser D, Carpp LN, Áñez G, Woo W, McGarry A, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Corey L, Neuzil KM, Follmann D, Ake JA, Gay CL, Kotloff KL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team.","Nat Commun. 2023 Mar 22;14(1):1581. doi: 10.1038/s41467-023-37367-2.","Fong Y","Nat Commun","2023","2023/03/23","PMC10031713","","10.1038/s41467-023-37367-2"
"33765086","Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection","Rolland M, Gilbert PB.","PLoS Pathog. 2021 Mar 25;17(3):e1009406. doi: 10.1371/journal.ppat.1009406. eCollection 2021 Mar.","Rolland M","PLoS Pathog","2021","2021/03/25","PMC7993616","","10.1371/journal.ppat.1009406"
"37330602","Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS.","Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w.","Follmann D","Nat Commun","2023","2023/06/17","PMC10276829","","10.1038/s41467-023-39292-w"
"35385469","Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention","Mayer BT, deCamp AC, Huang Y, Schiffer JT, Gottardo R, Gilbert PB, Reeves DB.","PLoS Comput Biol. 2022 Apr 6;18(4):e1010003. doi: 10.1371/journal.pcbi.1010003. eCollection 2022 Apr.","Mayer BT","PLoS Comput Biol","2022","2022/04/06","PMC9084525","","10.1371/journal.pcbi.1010003"
"34518674","A government-led effort to identify correlates of protection for COVID-19 vaccines","Koup RA, Donis RO, Gilbert PB, Li AW, Shah NA, Houchens CR.","Nat Med. 2021 Sep;27(9):1493-1494. doi: 10.1038/s41591-021-01484-6.","Koup RA","Nat Med","2021","2021/09/14","PMC9095364","NIHMS1800493","10.1038/s41591-021-01484-6"
"33859204","Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans","Seaton KE, Deal A, Han X, Li SS, Clayton A, Heptinstall J, Duerr A, Allen MA, Shen X, Sawant S, Yates NL, Spearman P, Churchyard G, Goepfert PA, Maenza J, Gray G, Pantaleo G, Polakowski L, Robinson HL, Grant S, Randhawa AK, Huang Y, Morgan C, Grunenberg N, Karuna S, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study Teams.","NPJ Vaccines. 2021 Apr 15;6(1):56. doi: 10.1038/s41541-021-00305-8.","Seaton KE","NPJ Vaccines","2021","2021/04/16","PMC8050318","","10.1038/s41541-021-00305-8"
"36357712","Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial","Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, Le Gars M, Van Roey GA, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Hyrien O, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Little SJ, Paiva de Sousa L, Maboa R, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, Neuzil KM, Carpp LN, Follmann D, Gilbert PB, Koup RA, Donis RO; Immune Assays Team; the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; and the United States Government (USG)/CoVPN Biostatistics Team.","Nat Microbiol. 2022 Dec;7(12):1996-2010. doi: 10.1038/s41564-022-01262-1. Epub 2022 Nov 10.","Fong Y","Nat Microbiol","2022","2022/11/10","PMC10166187","NIHMS1867012","10.1038/s41564-022-01262-1"
"18363776","Evaluating candidate principal surrogate endpoints","Gilbert PB, Hudgens MG.","Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.","Gilbert PB","Biometrics","2008","2008/03/28","PMC2726718","NIHMS92233","10.1111/j.1541-0420.2008.01014.x"
"35526218","Nonparametric estimation of the causal effect of a stochastic threshold-based intervention","van der Laan L, Zhang W, Gilbert PB.","Biometrics. 2023 Jun;79(2):1014-1028. doi: 10.1111/biom.13690. Epub 2022 May 26.","van der Laan L","Biometrics","2023","2022/05/08","PMC10024462","NIHMS1838367","10.1111/biom.13690"
"21517791","Comparing biomarkers as principal surrogate endpoints","Huang Y, Gilbert PB.","Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.","Huang Y","Biometrics","2011","2011/04/27","PMC3163011","NIHMS284893","10.1111/j.1541-0420.2011.01603.x"
"26853642","Search continues for a CMV vaccine for transplant recipients","Boeckh M, Gilbert PB.","Lancet Haematol. 2016 Feb;3(2):e58-9. doi: 10.1016/S2352-3026(15)00286-0. Epub 2015 Dec 24.","Boeckh M","Lancet Haematol","2016","2016/02/09","PMC6294316","NIHMS848878","10.1016/S2352-3026(15)00286-0"
"37396148","Robust joint modelling of left-censored longitudinal data and survival data with application to HIV vaccine studies","Yu T, Wu L, Qiu J, Gilbert PB.","Ann Appl Stat. 2023 Jun;17(2):1017-1037. doi: 10.1214/22-aoas1656. Epub 2023 May 1.","Yu T","Ann Appl Stat","2023","2023/07/03","PMC10312337","NIHMS1836716","10.1214/22-aoas1656"
"29701875","Estimation of the optimal surrogate based on a randomized trial","Price BL, Gilbert PB, van der Laan MJ.","Biometrics. 2018 Dec;74(4):1271-1281. doi: 10.1111/biom.12879. Epub 2018 Apr 27.","Price BL","Biometrics","2018","2018/04/28","PMC6393111","NIHMS1011305","10.1111/biom.12879"
"23926226","nCal: an R package for non-linear calibration","Fong Y, Sebestyen K, Yu X, Gilbert P, Self S.","Bioinformatics. 2013 Oct 15;29(20):2653-4. doi: 10.1093/bioinformatics/btt456. Epub 2013 Aug 6.","Fong Y","Bioinformatics","2013","2013/08/09","PMC3789552","","10.1093/bioinformatics/btt456"
"35801995","A varying-coefficient partially linear transformation model for length-biased data with an application to HIV vaccine studies","Wan ATK, Zhao W, Gilbert P, Zhou Y.","Int J Biostat. 2022 Jul 11;19(1):131-162. doi: 10.1515/ijb-2021-0057. eCollection 2023 May 1.","Wan ATK","Int J Biostat","2022","2022/07/08","PMC9832178","NIHMS1836199","10.1515/ijb-2021-0057"
"35022577","Publisher Correction: Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis","Koup RA, Donis RO, Gilbert PB, Li AW, Shah NA, Houchens CR.","Nat Med. 2022 Jan;28(1):214. doi: 10.1038/s41591-021-01671-5.","Koup RA","Nat Med","2022","2022/01/13","","","10.1038/s41591-021-01671-5"
"28670687","Improved estimation of the cumulative incidence of rare outcomes","Benkeser D, Carone M, Gilbert PB.","Stat Med. 2018 Jan 30;37(2):280-293. doi: 10.1002/sim.7337. Epub 2017 Jul 2.","Benkeser D","Stat Med","2018","2017/07/04","PMC5735003","NIHMS874568","10.1002/sim.7337"
"36899062","Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine","Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, Neuzil KM, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team.","NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0.","Benkeser D","NPJ Vaccines","2023","2023/03/10","PMC10005913","","10.1038/s41541-023-00630-0"
"32970635","CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","Duke ER, Williamson BD, Borate B, Golob JL, Wychera C, Stevens-Ayers T, Huang ML, Cossrow N, Wan H, Mast TC, Marks MA, Flowers ME, Jerome KR, Corey L, Gilbert PB, Schiffer JT, Boeckh M.","J Clin Invest. 2021 Jan 4;131(1):e133960. doi: 10.1172/JCI133960.","Duke ER","J Clin Invest","2021","2020/09/24","PMC7773411","","10.1172/JCI133960"
"34877661","Semiparametric additive time-varying coefficients model for longitudinal data with censored time origin","Sun Y, Shou Q, Gilbert PB, Heng F, Qian X.","Biometrics. 2023 Jun;79(2):695-710. doi: 10.1111/biom.13610. Epub 2022 Mar 20.","Sun Y","Biometrics","2023","2021/12/08","PMC9275555","NIHMS1817314","10.1111/biom.13610"
"34186015","Timing HIV infection with a simple and accurate population viral dynamics model","Reeves DB, Rolland M, Dearlove BL, Li Y, Robb ML, Schiffer JT, Gilbert P, Cardozo-Ojeda EF, Mayer BT.","J R Soc Interface. 2021 Jun;18(179):20210314. doi: 10.1098/rsif.2021.0314. Epub 2021 Jun 30.","Reeves DB","J R Soc Interface","2021","2021/06/29","PMC8241492","","10.1098/rsif.2021.0314"
"31827312","Analysis of generalized semiparametric mixed varying-coefficients models for longitudinal data","Sun Y, Qi L, Heng F, Gilbert PB.","Can J Stat. 2019 Sep;47(3):352-373. doi: 10.1002/cjs.11498. Epub 2019 May 1.","Sun Y","Can J Stat","2019","2019/12/13","PMC6905629","NIHMS1022051","10.1002/cjs.11498"
"34401888","Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial","Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi N, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Kutner M, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA.","medRxiv. 2021 Aug 15:2021.08.09.21261290. doi: 10.1101/2021.08.09.21261290. Preprint.","Gilbert PB","medRxiv","2021","2021/08/17","PMC8366808","","10.1101/2021.08.09.21261290"
"33244440","Assessing trends in vaccine efficacy by pathogen genetic distance","Benkeser D, Juraska M, Gilbert PB.","J Soc Fr Statistique (2009). 2020 Jul;161(1):164-175.","Benkeser D","J Soc Fr Statistique (2009)","2020","2020/11/27","PMC7685316","NIHMS1645265",""
"34907214","Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation","Huang Y, Borisov O, Kee JJ, Carpp LN, Wrin T, Cai S, Sarzotti-Kelsoe M, McDanal C, Eaton A, Pajon R, Hural J, Posavad CM, Gill K, Karuna S, Corey L, McElrath MJ, Gilbert PB, Petropoulos CJ, Montefiori DC.","Sci Rep. 2021 Dec 14;11(1):23921. doi: 10.1038/s41598-021-03154-6.","Huang Y","Sci Rep","2021","2021/12/15","PMC8671391","","10.1038/s41598-021-03154-6"
"31189712","Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial","Zolla-Pazner S, Gilbert PB.","J Virol. 2019 Aug 13;93(17):e00629-19. doi: 10.1128/JVI.00629-19. Print 2019 Sep 1.","Zolla-Pazner S","J Virol","2019","2019/06/14","PMC6694814","","10.1128/JVI.00629-19"
"34494017","Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation","Huang Y, Borisov O, Kee JJ, Carpp LN, Wrin T, Cai S, Sarzotti-Kelsoe M, McDanal C, Eaton A, Pajon R, Hural J, Posavad CM, Gill K, Karuna S, Corey L, McElrath MJ, Gilbert PB, Petropoulos CJ, Montefiori DC.","Res Sq. 2021 Sep 2:rs.3.rs-862572. doi: 10.21203/rs.3.rs-862572/v1. Preprint.","Huang Y","Res Sq","2021","2021/09/08","PMC8423224","","10.21203/rs.3.rs-862572/v1"
"31649413","Estimating and Testing Vaccine Sieve Effects Using Machine Learning","Benkeser D, Gilbert PB, Carone M.","J Am Stat Assoc. 2019;114(527):1038-1049. doi: 10.1080/01621459.2018.1529594. Epub 2019 Apr 3.","Benkeser D","J Am Stat Assoc","2019","2019/10/26","PMC6812562","NIHMS1520318","10.1080/01621459.2018.1529594"
"26006008","COMPASS identifies T-cell subsets correlated with clinical outcomes","Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ, Karasavvas N, Gilbert P, C De Rosa S, McElrath MJ, Gottardo R.","Nat Biotechnol. 2015 Jun;33(6):610-6. doi: 10.1038/nbt.3187. Epub 2015 May 25.","Lin L","Nat Biotechnol","2015","2015/05/26","PMC4569006","NIHMS721011","10.1038/nbt.3187"
"34545372","Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation","Huang Y, Borisov O, Kee JJ, Carpp LN, Wrin T, Cai S, Sarzotti-Kelsoe M, McDanal C, Eaton A, Pajon R, Hural J, Posavad CM, Gill K, Karuna S, Corey L, McElrath MJ, Gilbert PB, Petropoulos CJ, Montefiori DC.","medRxiv. 2021 Sep 14:2021.09.09.21263049. doi: 10.1101/2021.09.09.21263049. Preprint.","Huang Y","medRxiv","2021","2021/09/21","PMC8452111","","10.1101/2021.09.09.21263049"
"37008748","SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION","Huang Y, Zhuang Y, Gilbert P.","Ann Appl Stat. 2022 Sep;16(3):1774-1794. doi: 10.1214/21-aoas1566. Epub 2022 Jul 19.","Huang Y","Ann Appl Stat","2022","2023/04/03","PMC10065750","NIHMS1836703","10.1214/21-aoas1566"
"30933973","Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features","Magaret CA, Benkeser DC, Williamson BD, Borate BR, Carpp LN, Georgiev IS, Setliff I, Dingens AS, Simon N, Carone M, Simpkins C, Montefiori D, Alter G, Yu WH, Juraska M, Edlefsen PT, Karuna S, Mgodi NM, Edugupanti S, Gilbert PB.","PLoS Comput Biol. 2019 Apr 1;15(4):e1006952. doi: 10.1371/journal.pcbi.1006952. eCollection 2019 Apr.","Magaret CA","PLoS Comput Biol","2019","2019/04/02","PMC6459550","","10.1371/journal.pcbi.1006952"
"31589165","Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team; Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD.","J Clin Invest. 2019 Nov 1;129(11):4838-4849. doi: 10.1172/JCI126391.","Neidich SD","J Clin Invest","2019","2019/10/08","PMC6819135","","10.1172/JCI126391"
"37384759","Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials","Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, Matten D, Lambson B, Modise T, Kgagudi P, York T, Westfall DH, Giorgi EE, Korber B, Anthony C, Mapengo RE, Bekker V, Domin E, Eaton A, Deng W, DeCamp A, Huang Y, Gilbert PB, Gwashu-Nyangiwe A, Thebus R, Ndabambi N, Mielke D, Mgodi N, Karuna S, Edupuganti S, Seaman MS, Corey L, Cohen MS, Hural J, McElrath MJ, Mullins JI, Montefiori D, Moore PL, Williamson C, Morris L.","PLoS Pathog. 2023 Jun 29;19(6):e1011469. doi: 10.1371/journal.ppat.1011469. eCollection 2023 Jun.","Mkhize NN","PLoS Pathog","2023","2023/06/29","PMC10337935","","10.1371/journal.ppat.1011469"
"35441174","Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial","Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, Gars ML, Van Roey GA, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Hyrien O, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Little SJ, de Sousa LP, Maboa R, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, Neuzil KM, Carpp LN, Follmann D, Gilbert PB, Koup RA, Donis RO; Janssen Team; Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; United States Government (USG)/CoVPN Biostatistics Team.","medRxiv. 2022 Apr 12:2022.04.06.22272763. doi: 10.1101/2022.04.06.22272763. Preprint.","Fong Y","medRxiv","2022","2022/04/20","PMC9016647","","10.1101/2022.04.06.22272763"
"37385888","Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials","Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A; COVID-19 Prevention Network CoVPN.","Vaccine. 2023 Jul 25;41(33):4899-4906. doi: 10.1016/j.vaccine.2023.06.066. Epub 2023 Jun 23.","Turley CB","Vaccine","2023","2023/06/29","PMC10288314","","10.1016/j.vaccine.2023.06.066"
"30787294","Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine","Fourati S, Ribeiro SP, Blasco Tavares Pereira Lopes F, Talla A, Lefebvre F, Cameron M, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Rerks-Ngarm S, Kim JH, Thomas R, Gilbert PB, Tomaras GD, Koup RA, Michael NL, McElrath MJ, Gottardo R, Sékaly RP.","Nat Commun. 2019 Feb 20;10(1):863. doi: 10.1038/s41467-019-08854-2.","Fourati S","Nat Commun","2019","2019/02/22","PMC6382801","","10.1038/s41467-019-08854-2"
"25454855","Use of placebos in Phase 1 preventive HIV vaccine clinical trials","Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.","Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.","Huang Y","Vaccine","2015","2014/12/03","PMC4554766","NIHMS715614","10.1016/j.vaccine.2014.10.017"
"30247601","Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials","Gilbert PB, Luedtke AR.","J Infect Dis. 2018 Sep 22;218(suppl_2):S99-S101. doi: 10.1093/infdis/jiy421.","Gilbert PB","J Infect Dis","2018","2018/09/25","PMC6151089","","10.1093/infdis/jiy421"
"34213402","Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants","Huang Y, Zhang L, Eaton A, Mkhize NN, Carpp LN, Rudnicki E, DeCamp A, Juraska M, Randhawa A, McDermott A, Ledgerwood J, Andrew P, Karuna S, Edupuganti S, Mgodi N, Cohen M, Corey L, Mascola J, Gilbert PB, Morris L, Montefiori DC.","Hum Vaccin Immunother. 2022 Dec 31;18(1):1908030. doi: 10.1080/21645515.2021.1908030. Epub 2021 Jul 2.","Huang Y","Hum Vaccin Immunother","2022","2021/07/02","PMC8928800","","10.1080/21645515.2021.1908030"
"26229114","HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies","Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton KE, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath MJ, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF.","Science. 2015 Aug 14;349(6249):aab1253. doi: 10.1126/science.aab1253. Epub 2015 Jul 30.","Williams WB","Science","2015","2015/08/01","PMC4562404","NIHMS717270","10.1126/science.aab1253"
"32080888","A regularized estimation approach for case-cohort periodic follow-up studies with an application to HIV vaccine trials","Zhao H, Wu Q, Gilbert PB, Chen YQ, Sun J.","Biom J. 2020 Sep;62(5):1176-1191. doi: 10.1002/bimj.201900180. Epub 2020 Feb 20.","Zhao H","Biom J","2020","2020/02/22","PMC7768636","NIHMS1654631","10.1002/bimj.201900180"
"29897841","Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA.","N Engl J Med. 2018 Jul 26;379(4):327-340. doi: 10.1056/NEJMoa1800820. Epub 2018 Jun 13.","Sridhar S","N Engl J Med","2018","2018/06/14","","","10.1056/NEJMoa1800820"
"30623732","Methods for comparing durability of immune responses between vaccine regimens in early-phase trials","Westling T, Juraska M, Seaton KE, Tomaras GD, Gilbert PB, Janes H.","Stat Methods Med Res. 2020 Jan;29(1):78-93. doi: 10.1177/0962280218820881. Epub 2019 Jan 9.","Westling T","Stat Methods Med Res","2020","2019/01/10","PMC6682462","NIHMS1043746","10.1177/0962280218820881"
"26995733","Analysis of two-phase sampling data with semiparametric additive hazards models","Sun Y, Qian X, Shou Q, Gilbert PB.","Lifetime Data Anal. 2017 Jul;23(3):377-399. doi: 10.1007/s10985-016-9363-2. Epub 2016 Mar 19.","Sun Y","Lifetime Data Anal","2017","2016/03/21","PMC5309201","NIHMS846742","10.1007/s10985-016-9363-2"
"36684526","Simulation-Based Pharmacokinetics Sampling Design for Evaluating Correlates of Prevention Efficacy of Passive HIV Monoclonal Antibody Prophylaxis","Zhang L, Gilbert PB, Capparelli E, Huang Y.","Stat Biopharm Res. 2022;14(4):611-625. doi: 10.1080/19466315.2021.1919196. Epub 2021 Jun 28.","Zhang L","Stat Biopharm Res","2022","2023/01/23","PMC9856202","NIHMS1757617","10.1080/19466315.2021.1919196"
"36689221","Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials","Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network.","JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974.","Mena Lora AJ","JAMA Netw Open","2023","2023/01/23","","","10.1001/jamanetworkopen.2022.51974"
"33777613","Post-randomization Biomarker Effect Modification Analysis in an HIV Vaccine Clinical Trial","Gilbert PB, Blette BS, Shepherd BE, Hudgens MG.","J Causal Inference. 2020;8(1):54-69. doi: 10.1515/jci-2019-0022. Epub 2020 Jul 25.","Gilbert PB","J Causal Inference","2020","2021/03/29","PMC7996712","NIHMS1644671","10.1515/jci-2019-0022"
"26461462","Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark","Sun Y, Li M, Gilbert PB.","Comput Stat Data Anal. 2016 Jan 1;93:348-358. doi: 10.1016/j.csda.2014.11.012. Epub 2014 Dec 3.","Sun Y","Comput Stat Data Anal","2016","2015/10/14","PMC4598956","NIHMS646279","10.1016/j.csda.2014.11.012"
"29892140","Analysis of Generalized Semiparametric Regression Models for Cumulative Incidence Functions with Missing Covariates","Lee U, Sun Y, Scheike TH, Gilbert PB.","Comput Stat Data Anal. 2018 Jun;122:59-79. doi: 10.1016/j.csda.2018.01.003. Epub 2018 Feb 2.","Lee U","Comput Stat Data Anal","2018","2018/06/13","PMC5993453","NIHMS936358","10.1016/j.csda.2018.01.003"
"33720973","Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk","Andersen-Nissen E, Fiore-Gartland A, Ballweber Fleming L, Carpp LN, Naidoo AF, Harper MS, Voillet V, Grunenberg N, Laher F, Innes C, Bekker LG, Kublin JG, Huang Y, Ferrari G, Tomaras GD, Gray G, Gilbert PB, McElrath MJ.","PLoS Pathog. 2021 Mar 15;17(3):e1009363. doi: 10.1371/journal.ppat.1009363. eCollection 2021 Mar.","Andersen-Nissen E","PLoS Pathog","2021","2021/03/15","PMC7959397","","10.1371/journal.ppat.1009363"
"24337534","Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy","Gabriel EE, Gilbert PB.","Biostatistics. 2014 Apr;15(2):251-65. doi: 10.1093/biostatistics/kxt055. Epub 2013 Dec 13.","Gabriel EE","Biostatistics","2014","2013/12/17","PMC3944974","","10.1093/biostatistics/kxt055"
"31534016","Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa","Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.","Sci Transl Med. 2019 Sep 18;11(510):eaax1880. doi: 10.1126/scitranslmed.aax1880.","Gray GE","Sci Transl Med","2019","2019/09/20","PMC7199879","NIHMS1054745","10.1126/scitranslmed.aax1880"
"35841889","HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype","Li SS, Hickey A, Shangguan S, Ehrenberg PK, Geretz A, Butler L, Kundu G, Apps R, Creegan M, Clifford RJ, Pinyakorn S, Eller LA, Luechai P, Gilbert PB, Holtz TH, Chitwarakorn A, Sacdalan C, Kroon E, Phanuphak N, de Souza M, Ananworanich J, O'Connell RJ, Robb ML, Michael NL, Vasan S, Thomas R.","Cell Host Microbe. 2022 Aug 10;30(8):1173-1185.e8. doi: 10.1016/j.chom.2022.06.005. Epub 2022 Jul 15.","Li SS","Cell Host Microbe","2022","2022/07/16","PMC9380401","NIHMS1817876","10.1016/j.chom.2022.06.005"
"32274677","Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes","Heng F, Sun Y, Hyun S, Gilbert PB.","Lifetime Data Anal. 2020 Oct;26(4):731-760. doi: 10.1007/s10985-020-09497-y. Epub 2020 Apr 9.","Heng F","Lifetime Data Anal","2020","2020/04/11","PMC7487047","NIHMS1583633","10.1007/s10985-020-09497-y"
"34080723","Semiparametric regression analysis of partly interval-censored failure time data with application to an AIDS clinical trial","Zhou Q, Sun Y, Gilbert PB.","Stat Med. 2021 Sep 10;40(20):4376-4394. doi: 10.1002/sim.9035. Epub 2021 May 26.","Zhou Q","Stat Med","2021","2021/06/03","PMC9080514","NIHMS1799147","10.1002/sim.9035"
"30740005","Smoothed Rank Regression for the Accelerated Failure Time Competing Risks Model with Missing Cause of Failure","Qiu Z, Wan ATK, Zhou Y, Gilbert PB.","Stat Sin. 2019 Jan;29(1):23-46. doi: 10.5705/ss.202016.0231.","Qiu Z","Stat Sin","2019","2019/02/12","PMC6364751","NIHMS885063","10.5705/ss.202016.0231"
"27037797","Power/sample size calculations for assessing correlates of risk in clinical efficacy trials","Gilbert PB, Janes HE, Huang Y.","Stat Med. 2016 Sep 20;35(21):3745-59. doi: 10.1002/sim.6952. Epub 2016 Mar 31.","Gilbert PB","Stat Med","2016","2016/04/03","PMC4965346","NIHMS773751","10.1002/sim.6952"
"37300931","Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition","Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, Rossenkhan R, Giorgi EE, Kenny A, Angier H, Randhawa A, Weiner JA, Rojas M, Sarzotti-Kelsoe M, Zhang L, Sawant S, Ackerman ME, McDermott AB, Mascola JR, Hural J, McElrath MJ, Andrew P, Hidalgo JA, Clark J, Laher F, Orrell C, Frank I, Gonzales P, Edupuganti S, Mgodi N, Corey L, Morris L, Montefiori D, Cohen MS, Gilbert PB, Tomaras GD.","EBioMedicine. 2023 Jul;93:104590. doi: 10.1016/j.ebiom.2023.104590. Epub 2023 Jun 8.","Seaton KE","EBioMedicine","2023","2023/06/10","PMC10363420","","10.1016/j.ebiom.2023.104590"
"26180102","HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition","Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O'Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R.","Sci Transl Med. 2015 Jul 15;7(296):296ra112. doi: 10.1126/scitranslmed.aab4005.","Prentice HA","Sci Transl Med","2015","2015/07/17","PMC4911012","NIHMS792334","10.1126/scitranslmed.aab4005"
"31313349","Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials","Gilbert PB, Zhang Y, Rudnicki E, Huang Y.","Stat Med. 2019 Oct 15;38(23):4503-4518. doi: 10.1002/sim.8310. Epub 2019 Jul 17.","Gilbert PB","Stat Med","2019","2019/07/18","PMC6736712","NIHMS1037312","10.1002/sim.8310"
"29683765","Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials","Huang Y, Karuna S, Carpp LN, Reeves D, Pegu A, Seaton K, Mayer K, Schiffer J, Mascola J, Gilbert PB.","Hum Vaccin Immunother. 2018;14(9):2116-2127. doi: 10.1080/21645515.2018.1462640. Epub 2018 May 24.","Huang Y","Hum Vaccin Immunother","2018","2018/04/24","PMC6183277","","10.1080/21645515.2018.1462640"
"36787249","Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults","Cohen KW, Fiore-Gartland A, Walsh SR, Yusim K, Frahm N, Elizaga ML, Maenza J, Scott H, Mayer KH, Goepfert PA, Edupuganti S, Pantaleo G, Hutter J, Morris DE, De Rosa SC, Geraghty DE, Robb ML, Michael NL, Fischer W, Giorgi EE, Malhi H, Pensiero MN, Ferrari G, Tomaras GD, Montefiori DC, Gilbert PB, McElrath MJ, Haynes BF, Korber BT, Baden LR; NIAID HVTN 106 Study Group.","J Clin Invest. 2023 Feb 15;133(4):e163338. doi: 10.1172/JCI163338.","Cohen KW","J Clin Invest","2023","2023/02/14","PMC9927951","","10.1172/JCI163338"
"32421033","Generating Survival Times Using Cox Proportional Hazards Models with Cyclic and Piecewise Time-Varying Covariates","Huang Y, Zhang Y, Zhang Z, Gilbert PB.","Stat Biosci. 2020;12(3):324-339. doi: 10.1007/s12561-020-09266-3. Epub 2020 Jan 25.","Huang Y","Stat Biosci","2020","2020/05/19","PMC7223425","","10.1007/s12561-020-09266-3"
"31855881","Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01","Huang Y, Zhang Y, Bailer R, Grunenberg N, Carpp LN, Seaton K, Mayer KH, Ledgerwood J, Corey L, Mascola J, Montefiori D, Gilbert PB.","J Acquir Immune Defic Syndr. 2020 Apr 1;83(4):434-439. doi: 10.1097/QAI.0000000000002272.","Huang Y","J Acquir Immune Defic Syndr","2020","2019/12/20","PMC7594341","NIHMS1549606","10.1097/QAI.0000000000002272"
"30590450","Inference on treatment effect modification by biomarker response in a three-phase sampling design","Juraska M, Huang Y, Gilbert PB.","Biostatistics. 2020 Jul 1;21(3):545-560. doi: 10.1093/biostatistics/kxy074.","Juraska M","Biostatistics","2020","2018/12/28","PMC7308066","","10.1093/biostatistics/kxy074"
"36352021","Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy","Zhao LP, Lybrand TP, Gilbert PB, Payne TH, Pyo CW, Geraghty DE, Jerome KR.","Sci Rep. 2022 Nov 9;12(1):19089. doi: 10.1038/s41598-022-23342-2.","Zhao LP","Sci Rep","2022","2022/11/09","PMC9645309","","10.1038/s41598-022-23342-2"
"28757058","Immune correlates of protection for dengue: State of the art and research agenda","Katzelnick LC, Harris E; Participants in the Summit on Dengue Immune Correlates of Protection.","Vaccine. 2017 Aug 24;35(36):4659-4669. doi: 10.1016/j.vaccine.2017.07.045. Epub 2017 Jul 28.","Katzelnick LC","Vaccine","2017","2017/08/01","PMC5924688","NIHMS960371","10.1016/j.vaccine.2017.07.045"
"22299708","Assessing treatment-selection markers using a potential outcomes framework","Huang Y, Gilbert PB, Janes H.","Biometrics. 2012 Sep;68(3):687-96. doi: 10.1111/j.1541-0420.2011.01722.x. Epub 2012 Feb 2.","Huang Y","Biometrics","2012","2012/02/04","PMC3417090","NIHMS373252","10.1111/j.1541-0420.2011.01722.x"
"25352131","Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints","Gabriel EE, Sachs MC, Gilbert PB.","Stat Med. 2015 Feb 10;34(3):381-95. doi: 10.1002/sim.6349. Epub 2014 Oct 28.","Gabriel EE","Stat Med","2015","2014/10/30","PMC4801510","NIHMS760160","10.1002/sim.6349"
"36068106","Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia","Qi L, Sun Y, Juraska M, Moodie Z, Magaret CA, Heng F, Carpp LN, Gilbert PB.","Vaccine. 2022 Sep 29;40(41):5912-5923. doi: 10.1016/j.vaccine.2022.08.055. Epub 2022 Sep 5.","Qi L","Vaccine","2022","2022/09/06","PMC9881745","NIHMS1867191","10.1016/j.vaccine.2022.08.055"
"33336213","Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials","Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, Sahly HE, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM.","medRxiv. 2020 Dec 14:2020.12.14.20248137. doi: 10.1101/2020.12.14.20248137. Preprint.","Follmann D","medRxiv","2020","2020/12/18","PMC7745130","","10.1101/2020.12.14.20248137"
"26722639","Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition","Gilbert PB, Gabriel EE, Huang Y, Chan IS.","J Causal Inference. 2015 Sep 1;3(2):157-175. doi: 10.1515/jci-2014-0007. Epub 2015 Feb 1.","Gilbert PB","J Causal Inference","2015","2016/01/02","PMC4692254","NIHMS743251","10.1515/jci-2014-0007"
"36655191","Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial","Fong Y, Huang Y, Borate B, van der Laan LWP, Zhang W, Carpp LN, Cho I, Glenn G, Fries L, Gottardo R, Gilbert PB.","Open Forum Infect Dis. 2023 Jan 12;10(1):ofac693. doi: 10.1093/ofid/ofac693. eCollection 2023 Jan.","Fong Y","Open Forum Infect Dis","2023","2023/01/19","PMC9835761","","10.1093/ofid/ofac693"
"23878319","Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection","Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.","J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.","Janes H","J Infect Dis","2013","2013/07/24","PMC3778967","","10.1093/infdis/jit322"
"33493795","Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials","Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, Gonzales P, McDermott A, Ledgerwood J, Lorenzo MMG, Burns D, DeCamp A, Juraska M, Mascola J, Edupuganti S, Mgodi N, Cohen M, Corey L, Andrew P, Karuna S, Gilbert PB, Mngadi K, Lazarus E.","EBioMedicine. 2021 Feb;64:103203. doi: 10.1016/j.ebiom.2020.103203. Epub 2021 Jan 23.","Huang Y","EBioMedicine","2021","2021/01/25","PMC7841500","","10.1016/j.ebiom.2020.103203"
"37075127","Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial","Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, El Sahly HM, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB; Immune Assays; Moderna Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); United States Government (USG)/CoVPN Biostatistics Teams.","Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078. Epub 2023 Apr 19.","Benkeser D","Sci Transl Med","2023","2023/04/19","PMC10243212","NIHMS1899084","10.1126/scitranslmed.ade9078"
"36243351","Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data","Cohen D, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Baran TZ, Muhsen K, Gilbert PB, MacLennan CA.","Clin Microbiol Infect. 2023 Mar;29(3):366-371. doi: 10.1016/j.cmi.2022.10.011. Epub 2022 Oct 13.","Cohen D","Clin Microbiol Infect","2023","2022/10/15","PMC9993342","","10.1016/j.cmi.2022.10.011"
"27007859","Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling","Fu R, Gilbert PB.","Lifetime Data Anal. 2017 Jan;23(1):136-159. doi: 10.1007/s10985-016-9364-1. Epub 2016 Mar 23.","Fu R","Lifetime Data Anal","2017","2016/03/24","PMC5035179","NIHMS772253","10.1007/s10985-016-9364-1"
"22561365","Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team.","J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4.","Duerr A","J Infect Dis","2012","2012/05/08","PMC3490694","","10.1093/infdis/jis342"
"22049267","Commentary on ""Principal stratification - a goal or a tool?"" by Judea Pearl","Gilbert PB, Hudgens MG, Wolfson J.","Int J Biostat. 2011;7(1):Article 36. doi: 10.2202/1557-4679.1341. Epub 2011 Sep 20.","Gilbert PB","Int J Biostat","2011","2011/11/04","PMC3204668","","10.2202/1557-4679.1341"
"35233566","Rapidly Identifying New Coronavirus Mutations of Potential Concern in the Omicron Variant Using an Unsupervised Learning Strategy","Zhao LP, Lybrand T, Gilbert P, Payne TH, Pyo CW, Geraghty D, Jerome K.","Res Sq. 2022 Feb 25:rs.3.rs-1280819. doi: 10.21203/rs.3.rs-1280819/v1. Preprint.","Zhao LP","Res Sq","2022","2022/03/02","PMC8887078","","10.21203/rs.3.rs-1280819/v1"
"23243491","HIV Vaccine Trials Network: activities and achievements of the first decade and beyond","Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L.","Clin Investig (Lond). 2012 Mar;2(3):245-254. doi: 10.4155/cli.12.8.","Kublin JG","Clin Investig (Lond)","2012","2012/12/18","PMC3521567","NIHMS424857","10.4155/cli.12.8"
"23667279","Partially hidden Markov model for time-varying principal stratification in HIV prevention trials","Dai JY, Gilbert PB, Mâsse BR.","J Am Stat Assoc. 2012 Mar 1;107(497):52-65. doi: 10.1080/01621459.2011.643743.","Dai JY","J Am Stat Assoc","2012","2013/05/14","PMC3649016","NIHMS443999","10.1080/01621459.2011.643743"
"31117986","HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy","Gilbert PB, Fong Y, Juraska M, Carpp LN, Monto AS, Martin ET, Petrie JG.","BMC Infect Dis. 2019 May 22;19(1):453. doi: 10.1186/s12879-019-4049-5.","Gilbert PB","BMC Infect Dis","2019","2019/05/24","PMC6530189","","10.1186/s12879-019-4049-5"
"28379332","SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials","Fiore-Gartland A, Kullman N, deCamp AC, Clenaghan G, Yang W, Magaret CA, Edlefsen PT, Gilbert PB.","Bioinformatics. 2017 Aug 1;33(15):2386-2388. doi: 10.1093/bioinformatics/btx168.","Fiore-Gartland A","Bioinformatics","2017","2017/04/06","PMC5860116","","10.1093/bioinformatics/btx168"
"32084132","Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials","Reeves DB, Huang Y, Duke ER, Mayer BT, Cardozo-Ojeda EF, Boshier FA, Swan DA, Rolland M, Robb ML, Mascola JR, Cohen MS, Corey L, Gilbert PB, Schiffer JT.","PLoS Comput Biol. 2020 Feb 21;16(2):e1007626. doi: 10.1371/journal.pcbi.1007626. eCollection 2020 Feb.","Reeves DB","PLoS Comput Biol","2020","2020/02/22","PMC7055956","","10.1371/journal.pcbi.1007626"
"34533134","Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1","Shangguan S, Ehrenberg PK, Geretz A, Yum L, Kundu G, May K, Fourati S, Nganou-Makamdop K, Williams LD, Sawant S, Lewitus E, Pitisuttithum P, Nitayaphan S, Chariyalertsak S, Rerks-Ngarm S, Rolland M, Douek DC, Gilbert P, Tomaras GD, Michael NL, Vasan S, Thomas R.","Elife. 2021 Sep 17;10:e69577. doi: 10.7554/eLife.69577.","Shangguan S","Elife","2021","2021/09/17","PMC8514236","","10.7554/eLife.69577"
"34021743","Super LeArner Prediction of NAb Panels (SLAPNAP): a containerized tool for predicting combination monoclonal broadly neutralizing antibody sensitivity","Williamson BD, Magaret CA, Gilbert PB, Nizam S, Simmons C, Benkeser D.","Bioinformatics. 2021 Nov 18;37(22):4187-4192. doi: 10.1093/bioinformatics/btab398.","Williamson BD","Bioinformatics","2021","2021/05/22","PMC9502160","","10.1093/bioinformatics/btab398"
"29194547","Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America","Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, Noriega F, Gilbert PB.","J Infect Dis. 2018 Feb 14;217(5):742-753. doi: 10.1093/infdis/jix609.","Moodie Z","J Infect Dis","2018","2017/12/02","PMC5854020","","10.1093/infdis/jix609"
"27918612","Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations","Qi L, Sun Y, Gilbert PB.","Biometrics. 2017 Jun;73(2):441-451. doi: 10.1111/biom.12626. Epub 2016 Dec 5.","Qi L","Biometrics","2017","2016/12/06","PMC5459686","NIHMS839304","10.1111/biom.12626"
"31996422","Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection","Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, Churchyard G, Mayer KH, Karuna S, Morgan C, Bekker LG, Mlisana K, Gray G, Moodie Z, Gilbert P, Moore PL, Williamson C, Morris L.","mSphere. 2020 Jan 29;5(1):e00738-19. doi: 10.1128/mSphere.00738-19.","Ditse Z","mSphere","2020","2020/01/31","PMC6992371","","10.1128/mSphere.00738-19"
"26322580","HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders","Janes H, Herbeck JT, Tovanabutra S, Thomas R, Frahm N, Duerr A, Hural J, Corey L, Self SG, Buchbinder SP, McElrath MJ, O'Connell RJ, Paris RM, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, Robb ML, Michael NL, Mullins JI, Kim JH, Gilbert PB, Rolland M.","Nat Med. 2015 Oct;21(10):1139-41. doi: 10.1038/nm.3932. Epub 2015 Aug 31.","Janes H","Nat Med","2015","2015/09/01","PMC4598284","NIHMS711050","10.1038/nm.3932"
"36937899","Estimation of conditional cumulative incidence functions under generalized semiparametric regression models with missing covariates, with application to analysis of biomarker correlates in vaccine trials","Sun Y, Heng F, Lee U, Gilbert PB.","Can J Stat. 2023 Mar;51(1):235-257. doi: 10.1002/cjs.11693. Epub 2022 Feb 24.","Sun Y","Can J Stat","2023","2023/03/20","PMC10022693","NIHMS1775808","10.1002/cjs.11693"
"33844575","A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated","Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM.","Ann Intern Med. 2021 Aug;174(8):1118-1125. doi: 10.7326/M20-8149. Epub 2021 Apr 13.","Follmann D","Ann Intern Med","2021","2021/04/12","PMC8099035","","10.7326/M20-8149"
"34174082","Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials","Huang Y, Williamson BD, Moodie Z, Carpp LN, Chambonneau L, DiazGranados CA, Gilbert PB.","J Infect Dis. 2022 Jan 18;225(2):332-340. doi: 10.1093/infdis/jiab342.","Huang Y","J Infect Dis","2022","2021/06/26","PMC8915240","","10.1093/infdis/jiab342"
"36069983","Application of Statistical Learning to Identify Omicron Mutations in SARS-CoV-2 Viral Genome Sequence Data From Populations in Africa and the United States","Zhao LP, Lybrand TP, Gilbert P, Madeleine M, Payne TH, Cohen S, Geraghty DE, Jerome KR, Corey L.","JAMA Netw Open. 2022 Sep 1;5(9):e2230293. doi: 10.1001/jamanetworkopen.2022.30293.","Zhao LP","JAMA Netw Open","2022","2022/09/07","PMC9453543","","10.1001/jamanetworkopen.2022.30293"
"28368743","Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults","Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L, Gilbert PB.","MAbs. 2017 Jul;9(5):792-800. doi: 10.1080/19420862.2017.1311435. Epub 2017 Apr 3.","Huang Y","MAbs","2017","2017/04/04","PMC5524155","","10.1080/19420862.2017.1311435"
"35779963","Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021","Gilbert PB, Isbrucker R, Andrews N, Goldblatt D, Heath PT, Izu A, Madhi SA, Moulton L, Schrag SJ, Shang N, Siber G, Sobanjo-Ter Meulen A.","Vaccine. 2022 Jul 30;40(32):4283-4291. doi: 10.1016/j.vaccine.2022.05.016. Epub 2022 Jun 29.","Gilbert PB","Vaccine","2022","2022/07/02","","","10.1016/j.vaccine.2022.05.016"
"25646817","Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial","Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M; RV144 Sequencing Team; Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB.","PLoS Comput Biol. 2015 Feb 3;11(2):e1003973. doi: 10.1371/journal.pcbi.1003973. eCollection 2015 Feb.","Edlefsen PT","PLoS Comput Biol","2015","2015/02/04","PMC4315437","","10.1371/journal.pcbi.1003973"
"31827470","Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells","Fisher L, Zinter M, Stanfield-Oakley S, Carpp LN, Edwards RW, Denny T, Moodie Z, Laher F, Bekker LG, McElrath MJ, Gilbert PB, Corey L, Tomaras G, Pollara J, Ferrari G.","Front Immunol. 2019 Nov 27;10:2741. doi: 10.3389/fimmu.2019.02741. eCollection 2019.","Fisher L","Front Immunol","2019","2019/12/13","PMC6890556","","10.3389/fimmu.2019.02741"
"32949147","Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials","Hejazi NS, van der Laan MJ, Janes HE, Gilbert PB, Benkeser DC.","Biometrics. 2021 Dec;77(4):1241-1253. doi: 10.1111/biom.13375. Epub 2020 Sep 28.","Hejazi NS","Biometrics","2021","2020/09/19","PMC8016405","NIHMS1683482","10.1111/biom.13375"
"29666455","Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study","de Montigny S, Adamson BJS, Mâsse BR, Garrison LP Jr, Kublin JG, Gilbert PB, Dimitrov DT.","Sci Rep. 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.","de Montigny S","Sci Rep","2018","2018/04/19","PMC5904131","","10.1038/s41598-018-24268-4"
"31277299","Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment","Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT.","Viruses. 2019 Jul 3;11(7):607. doi: 10.3390/v11070607.","Rossenkhan R","Viruses","2019","2019/07/07","PMC6669737","","10.3390/v11070607"
"34635391","Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand","Thomas R, Chansinghakul D, Limkittikul K, Gilbert PB, Hattasingh W, Moodie Z, Shangguan S, Frago C, Dulyachai W, Li SS, Jarman RG, Geretz A, Bouckenooghe A, Sabchareon A, Juraska M, Ehrenberg P, Michael NL, Bailleux F, Bryant C, Gurunathan S.","Hum Immunol. 2022 Jan;83(1):53-60. doi: 10.1016/j.humimm.2021.09.006. Epub 2021 Oct 8.","Thomas R","Hum Immunol","2022","2021/10/12","","","10.1016/j.humimm.2021.09.006"
"35062214","Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning Strategy","Zhao LP, Lybrand TP, Gilbert PB, Hawn TR, Schiffer JT, Stamatatos L, Payne TH, Carpp LN, Geraghty DE, Jerome KR.","Viruses. 2021 Dec 21;14(1):9. doi: 10.3390/v14010009.","Zhao LP","Viruses","2021","2022/01/22","PMC8777887","","10.3390/v14010009"
"31748227","Antigenic competition in CD4(+) T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, Baden LR, Valencia J, Sobieszczyk M, Van Tieu H, Allen M, Hural J, Graham BS, Kublin J, Gilbert PB, Corey L, Goepfert PA, McElrath MJ, Johnson RP, Huang Y, Frahm N.","Sci Transl Med. 2019 Nov 20;11(519):eaaw1673. doi: 10.1126/scitranslmed.aaw1673.","Kallas EG","Sci Transl Med","2019","2019/11/22","PMC7003991","NIHMS1062357","10.1126/scitranslmed.aaw1673"
"30127007","Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, Girerd-Chambaz Y, Langevin E, Frago C, Guy B, Jackson N, Duong Thi Hue K, Simmons CP, Edlefsen PT, Gilbert PB.","Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8378-E8387. doi: 10.1073/pnas.1714250115. Epub 2018 Aug 20.","Juraska M","Proc Natl Acad Sci U S A","2018","2018/08/22","PMC6130398","","10.1073/pnas.1714250115"
"23409839","Design and estimation for evaluating principal surrogate markers in vaccine trials","Huang Y, Gilbert PB, Wolfson J.","Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.","Huang Y","Biometrics","2013","2013/02/16","PMC3713795","NIHMS482871","10.1111/biom.12014"
"31265429","Simultaneous Inference of Treatment Effect Modification by Intermediate Response Endpoint Principal Strata with Application to Vaccine Trials","Zhuang Y, Huang Y, Gilbert PB.","Int J Biostat. 2019 Jul 2;16(1):/j/ijb.2020.16.issue-1/ijb-2018-0058/ijb-2018-0058.xml. doi: 10.1515/ijb-2018-0058.","Zhuang Y","Int J Biostat","2019","2019/07/03","PMC6939148","NIHMS1049016","10.1515/ijb-2018-0058"
"31999736","Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans","Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, Michael NL, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, De Rosa SC, Corey L, Gray GE, Seaton KE, Yates NL, McElrath MJ, Frahm N, Tomaras GD, Gilbert PB.","PLoS One. 2020 Jan 30;15(1):e0226803. doi: 10.1371/journal.pone.0226803. eCollection 2020.","Zhao LP","PLoS One","2020","2020/01/31","PMC6992005","","10.1371/journal.pone.0226803"
"24187408","Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials","Gilbert PB, Shepherd BE, Hudgens MG.","J Am Stat Assoc. 2013 Jan 1;108(503):10.1080/01621459.2013.786649. doi: 10.1080/01621459.2013.786649.","Gilbert PB","J Am Stat Assoc","2013","2013/11/05","PMC3811958","NIHMS465175","10.1080/01621459.2013.786649"
"33587505","Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody","Edupuganti S, Mgodi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, Cohen MS, Corey L; HVTN 704/HPTN 085 study group.","J Acquir Immune Defic Syndr. 2021 May 1;87(1):671-679. doi: 10.1097/QAI.0000000000002639.","Edupuganti S","J Acquir Immune Defic Syndr","2021","2021/02/15","PMC8397466","NIHMS1667238","10.1097/QAI.0000000000002639"
"29028943","A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies","Yu T, Wu L, Gilbert PB.","Biostatistics. 2018 Jul 1;19(3):374-390. doi: 10.1093/biostatistics/kxx047.","Yu T","Biostatistics","2018","2017/10/14","PMC6193623","","10.1093/biostatistics/kxx047"
"28131393","Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials","Huang Y, Zhang L, Janes H, Frahm N, Isaacs A, Kim JH, Montefiori D, McElrath MJ, Tomaras GD, Gilbert PB.","Vaccine. 2017 Feb 22;35(8):1184-1193. doi: 10.1016/j.vaccine.2016.09.053. Epub 2017 Jan 25.","Huang Y","Vaccine","2017","2017/01/30","PMC5319823","NIHMS842454","10.1016/j.vaccine.2016.09.053"
"34159336","Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy","Zhao LP, Lybrand TP, Gilbert PB, Hawn TR, Schiffer JT, Stamatatos L, Payne TH, Carpp LN, Geraghty DE, Jerome KR.","bioRxiv. 2021 Jun 15:2021.06.15.448495. doi: 10.1101/2021.06.15.448495. Preprint.","Zhao LP","bioRxiv","2021","2021/06/23","PMC8219100","","10.1101/2021.06.15.448495"
"25267551","Finite-sample corrected generalized estimating equation of population average treatment effects in stepped wedge cluster randomized trials","Scott JM, deCamp A, Juraska M, Fay MP, Gilbert PB.","Stat Methods Med Res. 2017 Apr;26(2):583-597. doi: 10.1177/0962280214552092. Epub 2014 Sep 29.","Scott JM","Stat Methods Med Res","2017","2014/10/01","PMC4411204","NIHMS639039","10.1177/0962280214552092"
"27846073","Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence","Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.","J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608. doi: 10.1097/QAI.0000000000001160.","Hanscom B","J Acquir Immune Defic Syndr","2016","2016/11/16","PMC5175411","NIHMS809310","10.1097/QAI.0000000000001160"
"28107435","Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure","Aiyegbo MS, Shmelkov E, Dominguez L, Goger M, Battacharya S, deCamp AC, Gilbert PB, Berman PW, Cardozo T.","PLoS One. 2017 Jan 20;12(1):e0170530. doi: 10.1371/journal.pone.0170530. eCollection 2017.","Aiyegbo MS","PLoS One","2017","2017/01/21","PMC5249078","","10.1371/journal.pone.0170530"
"28678869","V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144","Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P, Montefiori DC.","PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017.","Perez LG","PLoS One","2017","2017/07/06","PMC5498072","","10.1371/journal.pone.0180720"
"33312415","Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs","Gilbert PB.","Stat Commun Infect Dis. 2019;11(1):20190003. doi: 10.1515/scid-2019-0003. Epub 2019 Jul 27.","Gilbert PB","Stat Commun Infect Dis","2019","2020/12/14","PMC7731930","NIHMS1049573","10.1515/scid-2019-0003"
"26511033","Mark-specific hazard ratio model with missing multivariate marks","Juraska M, Gilbert PB.","Lifetime Data Anal. 2016 Oct;22(4):606-25. doi: 10.1007/s10985-015-9353-9. Epub 2015 Oct 28.","Juraska M","Lifetime Data Anal","2016","2015/10/30","PMC4848257","NIHMS734070","10.1007/s10985-015-9353-9"
"33297341","Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP(®) DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults","Edupuganti S, C De Rosa S, Elizaga M, Lu Y, Han X, Huang Y, Swann E, Polakowski L, A Kalams S, Keefer M, Maenza J, C Wise M, Yan J, Morrow MP, Khan AS, Boyer JD, Humeau L, White S, Sardesai NY, Bagarazzi ML, Gilbert PB, Kublin JG, Corey L, Weiner DB, On Behalf Of The Hvtn Study Team, The Niaid-Funded Hiv Vaccine Trials Network.","Vaccines (Basel). 2020 Dec 7;8(4):741. doi: 10.3390/vaccines8040741.","Edupuganti S","Vaccines (Basel)","2020","2020/12/10","PMC7762306","","10.3390/vaccines8040741"
"29218117","Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials","Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.","Stat Commun Infect Dis. 2017 Jan;9(1):20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.","Gilbert PB","Stat Commun Infect Dis","2017","2017/12/09","PMC5714515","NIHMS898295","10.1515/scid-2016-0001"
"31513771","A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y.","Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.","Pegu A","Cell Host Microbe","2019","2019/09/13","PMC6755677","NIHMS1539171","10.1016/j.chom.2019.08.014"
"33369671","Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries","Huang Y, Moodie Z, Juraska M, Fong Y, Carpp LN, Chambonneau L, Coronel DL, Dayan GH, DiazGranados CA, Gilbert PB.","Trans R Soc Trop Med Hyg. 2021 Jul 1;115(7):750-763. doi: 10.1093/trstmh/traa154.","Huang Y","Trans R Soc Trop Med Hyg","2021","2020/12/28","PMC8245293","","10.1093/trstmh/traa154"
"17922394","A framework for assessing immunological correlates of protection in vaccine trials","Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG.","J Infect Dis. 2007 Nov 1;196(9):1304-12. doi: 10.1086/522428. Epub 2007 Oct 2.","Qin L","J Infect Dis","2007","2007/10/09","","","10.1086/522428"
"17266560","Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach","Li F, Gilbert PB, Self SG.","Curr HIV Res. 2007 Jan;5(1):87-96. doi: 10.2174/157016207779316305.","Li F","Curr HIV Res","2007","2007/02/03","","","10.2174/157016207779316305"
"37313548","Analysis of the Cox Model with Longitudinal Covariates with Measurement Errors and Partly Interval Censored Failure Times, with Application to an AIDS Clinical Trial","Sun Y, Zhou Q, Gilbert PB.","Stat Biosci. 2023;15(2):430-454. doi: 10.1007/s12561-023-09372-y. Epub 2023 May 20.","Sun Y","Stat Biosci","2023","2023/06/14","PMC10198790","","10.1007/s12561-023-09372-y"
"16426900","Statistical evaluation of HIV vaccines in early clinical trials","Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.","Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19.","Moodie Z","Contemp Clin Trials","2006","2006/01/24","","","10.1016/j.cct.2005.11.008"
"31434737","Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial","Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.","J Virol. 2019 Oct 15;93(21):e02041-18. doi: 10.1128/JVI.02041-18. Print 2019 Nov 1.","Li SS","J Virol","2019","2019/08/23","PMC6803257","","10.1128/JVI.02041-18"
"30543657","Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease","Pasin C, Halloran ME, Gilbert PB, Langevin E, Ochiai RL, Pitisuttithum P, Capeding MR, Carrasquilla G, Frago C, Cortés M, Chambonneau L, Moodie Z.","PLoS One. 2018 Dec 13;13(12):e0207878. doi: 10.1371/journal.pone.0207878. eCollection 2018.","Pasin C","PLoS One","2018","2018/12/14","PMC6292612","","10.1371/journal.pone.0207878"
"32204943","Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, Price B, Frago C, Bouckenooghe A, Cortes M, Noriega F, DiazGranados CA.","Vaccine. 2020 Apr 23;38(19):3531-3536. doi: 10.1016/j.vaccine.2020.03.029. Epub 2020 Mar 20.","Dayan GH","Vaccine","2020","2020/03/25","","","10.1016/j.vaccine.2020.03.029"
"28781713","Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials","Yang G, Sun Y, Qi L, Gilbert PB.","Stat Biosci. 2017 Jun;9(1):259-283. doi: 10.1007/s12561-016-9177-5. Epub 2016 Oct 27.","Yang G","Stat Biosci","2017","2017/08/08","PMC5540271","NIHMS850575","10.1007/s12561-016-9177-5"
"29488249","Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials","Sun Y, Qi L, Yang G, Gilbert PB.","Biom J. 2018 May;60(3):516-536. doi: 10.1002/bimj.201700002. Epub 2018 Feb 28.","Sun Y","Biom J","2018","2018/03/01","PMC6447062","NIHMS1521439","10.1002/bimj.201700002"
"32034163","HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens","Shen X, Laher F, Moodie Z, McMillan AS, Spreng RL, Gilbert PB, Huang Y, Yates NL, Grunenberg N, Juliana McElrath M, Allen M, Pensiero M, Mehra VL, Der Meeren OV, Barnett SW, Phogat S, Gray GE, Bekker LG, Corey L, Tomaras GD.","Sci Rep. 2020 Feb 7;10(1):2093. doi: 10.1038/s41598-020-57491-z.","Shen X","Sci Rep","2020","2020/02/09","PMC7005751","","10.1038/s41598-020-57491-z"
"27015273","FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells","Peng X, Li SS, Gilbert PB, Geraghty DE, Katze MG.","PLoS One. 2016 Mar 25;11(3):e0152425. doi: 10.1371/journal.pone.0152425. eCollection 2016.","Peng X","PLoS One","2016","2016/03/26","PMC4807760","","10.1371/journal.pone.0152425"
"24829343","Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial","Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.","J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.","Gartland AJ","J Virol","2014","2014/05/16","PMC4135964","","10.1128/JVI.01164-14"
"26332672","Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials","Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.","PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.","Huang Y","PLoS One","2015","2015/09/03","PMC4558095","","10.1371/journal.pone.0136626"
"19169384","A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact","Yang Y, Gilbert P, Longini IM, Halloran ME.","Ann Appl Stat. 2008;2(4):1409-1431. doi: 10.1214/08-AOAS193.","Yang Y","Ann Appl Stat","2008","2009/01/27","PMC2630256","NIHMS76672","10.1214/08-AOAS193"
"29149197","Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120","deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.","PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.","deCamp AC","PLoS One","2017","2017/11/18","PMC5693417","","10.1371/journal.pone.0185959"
"23813283","Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics","Dai JY, Li SS, Gilbert PB.","Biostatistics. 2014 Jan;15(1):196-203. doi: 10.1093/biostatistics/kxt018. Epub 2013 Jun 27.","Dai JY","Biostatistics","2014","2013/07/02","PMC3862206","","10.1093/biostatistics/kxt018"
"28493891","Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women","Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.","PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.","Gilbert PB","PLoS One","2017","2017/05/12","PMC5426618","","10.1371/journal.pone.0176428"
"19022314","Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials","Gilbert PB, Sato A, Sun X, Mehrotra DV.","Vaccine. 2009 Jan 14;27(3):396-401. doi: 10.1016/j.vaccine.2008.10.083. Epub 2008 Nov 18.","Gilbert PB","Vaccine","2009","2008/11/22","PMC2653280","NIHMS93872","10.1016/j.vaccine.2008.10.083"
"25599085","Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses","Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI, deSouza MS, Karasavvas N, Nitayaphan S, Rerks-Ngarm S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P.","EBioMedicine. 2014 Nov 1;1(1):37-45. doi: 10.1016/j.ebiom.2014.10.022.","Zolla-Pazner S","EBioMedicine","2014","2015/01/20","PMC4293639","NIHMS652687","10.1016/j.ebiom.2014.10.022"
"31115304","Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response","Gilbert PB, Huang Y, Juraska M, Moodie Z, Fong Y, Luedtke A, Zhuang Y, Shao J, Carpp LN, Jackson N, Chambonneau L, Bouckenooghe A, Zambrano B, Frago C, Pallardy S, Noriega F.","Am J Trop Med Hyg. 2019 Jul;101(1):164-179. doi: 10.4269/ajtmh.18-0534.","Gilbert PB","Am J Trop Med Hyg","2019","2019/05/23","PMC6609170","","10.4269/ajtmh.18-0534"
"31285781","NONPARAMETRIC INFERENCE FOR IMMUNE RESPONSE THRESHOLDS OF RISK IN VACCINE STUDIES","Donovan KM, Hudgens MG, Gilbert PB.","Ann Appl Stat. 2019 Jun;13(2):1147-1165. doi: 10.1214/18-AOAS1237. Epub 2019 Jun 17.","Donovan KM","Ann Appl Stat","2019","2019/07/10","PMC6613658","NIHMS1010537","10.1214/18-AOAS1237"
"19091857","Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo","Wick WD, Gilbert PB, Yang OO.","J Virol. 2009 Mar;83(5):2349-56. doi: 10.1128/JVI.00821-08. Epub 2008 Dec 17.","Wick WD","J Virol","2009","2008/12/19","PMC2643708","","10.1128/JVI.00821-08"
"32542024","Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America","Carpp LN, Fong Y, Bonaparte M, Moodie Z, Juraska M, Huang Y, Price B, Zhuang Y, Shao J, Zheng L, Chambonneau L, Small R, Sridhar S, DiazGranados CA, Gilbert PB.","PLoS One. 2020 Jun 15;15(6):e0234236. doi: 10.1371/journal.pone.0234236. eCollection 2020.","Carpp LN","PLoS One","2020","2020/06/17","PMC7295445","","10.1371/journal.pone.0234236"
"17704528","The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy","Gilbert PB, McKeague IW, Sun Y.","Biostatistics. 2008 Apr;9(2):263-76. doi: 10.1093/biostatistics/kxm028. Epub 2007 Aug 17.","Gilbert PB","Biostatistics","2008","2007/08/21","","","10.1093/biostatistics/kxm028"
"25663743","Nonparametric Bounds and Sensitivity Analysis of Treatment Effects","Richardson A, Hudgens MG, Gilbert PB, Fine JP.","Stat Sci. 2014 Nov;29(4):596-618. doi: 10.1214/14-STS499.","Richardson A","Stat Sci","2014","2015/02/10","PMC4317325","NIHMS656326","10.1214/14-STS499"
"26368824","Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men","Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB, Robertson M, Kublin J, Corey L, Gray GE.","PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.","Moodie Z","PLoS One","2015","2015/09/15","PMC4569275","","10.1371/journal.pone.0137666"
"29325070","Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial","Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.","J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.","Fong Y","J Infect Dis","2018","2018/01/12","PMC6018910","","10.1093/infdis/jiy008"
"23302152","Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration","Dai JY, Gilbert PB, Hughes JP, Brown ER.","Am J Epidemiol. 2013 Feb 1;177(3):256-63. doi: 10.1093/aje/kws324. Epub 2013 Jan 9.","Dai JY","Am J Epidemiol","2013","2013/01/11","PMC3577049","","10.1093/aje/kws324"
"12495131","Simultaneous inferences on the contrast of two hazard functions with censored observations","Gilbert PB, Wei LJ, Kosorok MR, Clemens JD.","Biometrics. 2002 Dec;58(4):773-80. doi: 10.1111/j.0006-341x.2002.00773.x.","Gilbert PB","Biometrics","2002","2002/12/24","","","10.1111/j.0006-341x.2002.00773.x"
"16890329","Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation","Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG.","Vaccine. 2006 Nov 17;24(47-48):6893-904. doi: 10.1016/j.vaccine.2006.06.009. Epub 2006 Jun 27.","Li F","Vaccine","2006","2006/08/08","","","10.1016/j.vaccine.2006.06.009"
"25369172","Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study","Huang Y, Duerr A, Frahm N, Zhang L, Moodie Z, De Rosa S, McElrath MJ, Gilbert PB.","PLoS One. 2014 Nov 4;9(11):e108631. doi: 10.1371/journal.pone.0108631. eCollection 2014.","Huang Y","PLoS One","2014","2014/11/05","PMC4219669","","10.1371/journal.pone.0108631"
"28199679","Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial","Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.","J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.","Janes HE","J Infect Dis","2017","2017/02/16","PMC5853653","","10.1093/infdis/jix086"
"17979212","Evaluating a surrogate endpoint at three levels, with application to vaccine development","Gilbert PB, Qin L, Self SG.","Stat Med. 2008 Oct 15;27(23):4758-78. doi: 10.1002/sim.3122.","Gilbert PB","Stat Med","2008","2007/11/06","PMC2646675","NIHMS93478","10.1002/sim.3122"
"29898870","Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial","Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.","Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.","Bekker LG","Lancet HIV","2018","2018/06/15","PMC6028742","","10.1016/S2352-3018(18)30071-7"
"24504509","Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD.","PLoS One. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572. eCollection 2014.","Zolla-Pazner S","PLoS One","2014","2014/02/08","PMC3913641","","10.1371/journal.pone.0087572"
"23818843","HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1","Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N, Robertson MN, Graham BS, Gilbert P.","PLoS Pathog. 2013;9(6):e1003404. doi: 10.1371/journal.ppat.1003404. Epub 2013 Jun 20.","Hertz T","PLoS Pathog","2013","2013/07/03","PMC3688560","","10.1371/journal.ppat.1003404"
"27583368","Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants","Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L.","PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.","Churchyard G","PLoS One","2016","2016/09/02","PMC5008759","","10.1371/journal.pone.0161753"
"26863315","Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials","Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ.","PLoS One. 2016 Feb 10;11(2):e0147812. doi: 10.1371/journal.pone.0147812. eCollection 2016.","Fiore-Gartland A","PLoS One","2016","2016/02/11","PMC4749288","","10.1371/journal.pone.0147812"
"28931520","DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8(+) T-Cell Responses by Interleukin-12 Plasmid DNA","Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.","Clin Vaccine Immunol. 2017 Nov 6;24(11):e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.","Li SS","Clin Vaccine Immunol","2017","2017/09/22","PMC5674193","","10.1128/CVI.00263-17"
"26587311","Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals","Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ; NIAID HIV Vaccine Trials Network.","J AIDS Clin Res. 2015 May;6(5):461. doi: 10.4172/2155-6113.1000461. Epub 2015 May 23.","Fuchs JD","J AIDS Clin Res","2015","2015/11/21","PMC4648371","NIHMS722748","10.4172/2155-6113.1000461"
"20608874","Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine","Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.","J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.","Gilbert P","J Infect Dis","2010","2010/07/09","PMC2946208","NIHMS203838","10.1086/654816"
"21402548","Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials","Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG.","J Infect Dis. 2011 Apr 1;203(7):969-75. doi: 10.1093/infdis/jiq152.","Gilbert PB","J Infect Dis","2011","2011/03/16","PMC3068028","","10.1093/infdis/jiq152"
"28727817","Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults","Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.","PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.","Buchbinder SP","PLoS One","2017","2017/07/21","PMC5519050","","10.1371/journal.pone.0179597"
"19079758","ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL","Qin L, Gilbert PB, Follmann D, Li D.","Ann Appl Stat. 2008 Mar;2(1):386-407. doi: 10.1214/07-AOAS132.","Qin L","Ann Appl Stat","2008","2008/12/17","PMC2601643","NIHMS68128","10.1214/07-AOAS132"
"14601754","Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials","Gilbert PB, Bosch RJ, Hudgens MG.","Biometrics. 2003 Sep;59(3):531-41. doi: 10.1111/1541-0420.00063.","Gilbert PB","Biometrics","2003","2003/11/07","","","10.1111/1541-0420.00063"
"12590415","Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal","Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ.","Stat Med. 2003 Feb 28;22(4):573-93. doi: 10.1002/sim.1342.","Gilbert PB","Stat Med","2003","2003/02/19","","","10.1002/sim.1342"
"28154793","Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy","Gilbert PB, Huang Y.","Epidemiol Methods. 2016 Dec;5(1):93-112. doi: 10.1515/em-2015-0007. Epub 2016 Jan 23.","Gilbert PB","Epidemiol Methods","2016","2017/02/04","PMC5279575","NIHMS797808","10.1515/em-2015-0007"
"22952672","MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load","Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P.","PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.","Janes H","PLoS One","2012","2012/09/07","PMC3428369","","10.1371/journal.pone.0043396"
"24123289","Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials","Gilbert PB, Yu X, Rotnitzky A.","Stat Med. 2014 Mar 15;33(6):901-17. doi: 10.1002/sim.6006. Epub 2013 Oct 9.","Gilbert PB","Stat Med","2014","2013/10/15","PMC4021041","NIHMS582341","10.1002/sim.6006"
"24823623","Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS.","J Infect Dis. 2014 Nov 15;210(10):1573-81. doi: 10.1093/infdis/jiu279. Epub 2014 May 13.","Gilbert PB","J Infect Dis","2014","2014/05/15","PMC4215071","","10.1093/infdis/jiu279"
"24560541","Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study","Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.","Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.","Gray GE","Lancet Infect Dis","2014","2014/02/25","PMC4174314","NIHMS588579","10.1016/S1473-3099(14)70020-9"
"16379605","Covariability of selected amino acid positions for HIV type 1 subtypes C and B","Gilbert PB, Novitsky V, Essex M.","AIDS Res Hum Retroviruses. 2005 Dec;21(12):1016-30. doi: 10.1089/aid.2005.21.1016.","Gilbert PB","AIDS Res Hum Retroviruses","2005","2005/12/29","","","10.1089/aid.2005.21.1016"
"24086607","Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.","PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.","Gottardo R","PLoS One","2013","2013/10/03","PMC3784573","","10.1371/journal.pone.0075665"
"25253665","Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants","Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.","Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.","Frey SE","Clin Vaccine Immunol","2014","2014/09/26","PMC4248765","","10.1128/CVI.00450-14"
"25405724","Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge","Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, Lundebjerg S, Gilbert P, Van Voorhis WC, Whisler J, Wang R, Ockenhouse CF, Heppner DG, Kappe SH, Duffy PE.","PLoS One. 2014 Nov 18;9(11):e109654. doi: 10.1371/journal.pone.0109654. eCollection 2014.","Talley AK","PLoS One","2014","2014/11/19","PMC4236046","","10.1371/journal.pone.0109654"
"24660049","Statistical approaches to analyzing HIV-1 neutralizing antibody assay data","Yu X, Gilbert PB, Hioe CE, Zolla-Pazner S, Self SG.","Stat Biopharm Res. 2012 Jan 1;4(1):1-13. doi: 10.1080/19466315.2011.633860.","Yu X","Stat Biopharm Res","2012","2014/03/25","PMC3959164","NIHMS553500","10.1080/19466315.2011.633860"
"15295694","Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160","Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL.","J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29.","Lee D","J Infect Dis","2004","2004/08/06","","","10.1086/423284"
"19012954","Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.","Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.","Buchbinder SP","Lancet","2008","2008/11/18","PMC2721012","NIHMS108872","10.1016/S0140-6736(08)61591-3"
"12854072","What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials","Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L.","J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1.","Gilbert PB","J Infect Dis","2003","2003/07/11","","","10.1086/376449"
"37440227","Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials","Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN).","JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349.","Theodore DA","JAMA Netw Open","2023","2023/07/13","PMC10346130","","10.1001/jamanetworkopen.2023.23349"
"15688279","Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW.","J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27.","Gilbert PB","J Infect Dis","2005","2005/02/03","","","10.1086/428405"
"32092060","Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines","Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, Frahm N, Yates NL, Morris L, Malahleha M, Mngadi K, Daniels B, Innes C, Saunders K, Grant S, Yu C, Gilbert PB, Phogat S, DiazGranados CA, Koutsoukos M, Van Der Meeren O, Bentley C, Mkhize NN, Pensiero MN, Mehra VL, Kublin JG, Corey L, Montefiori DC, Gray GE, McElrath MJ, Tomaras GD.","PLoS Med. 2020 Feb 24;17(2):e1003038. doi: 10.1371/journal.pmed.1003038. eCollection 2020 Feb.","Laher F","PLoS Med","2020","2020/02/25","PMC7039414","","10.1371/journal.pmed.1003038"
"32442195","Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials","Moodie Z, Walsh SR, Laher F, Maganga L, Herce ME, Naidoo S, Hosseinipour MC, Innes C, Bekker LG, Grunenberg N, Mann P, Yu C, deCamp AC, Miner MD, Yates NL, Heptinstall J, Mkhize NN, Dintwe O, Frahm N, Cohen KW, Allen M, Hutter J, Wagner R, Pantaleo G, McElrath MJ, Tomaras GD, Morris L, Montefiori DC, Andersen-Nissen E, Gray GE, Gilbert PB, Kublin JG; NIAID HVTN 100 and HVTN 111 trial teams.","PLoS Med. 2020 May 22;17(5):e1003117. doi: 10.1371/journal.pmed.1003117. eCollection 2020 May.","Moodie Z","PLoS Med","2020","2020/05/23","PMC7244095","","10.1371/journal.pmed.1003117"
"31601541","Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial","Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.","Lancet HIV. 2019 Nov;6(11):e737-e749. doi: 10.1016/S2352-3018(19)30262-0. Epub 2019 Oct 7.","Pantaleo G","Lancet HIV","2019","2019/10/12","PMC7156919","","10.1016/S2352-3018(19)30262-0"
"25641990","Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to HIV vaccine efficacy trials","Gilbert PB, Sun Y.","J R Stat Soc Ser C Appl Stat. 2015 Jan 1;64(1):49-73. doi: 10.1111/rssc.12067.","Gilbert PB","J R Stat Soc Ser C Appl Stat","2015","2015/02/03","PMC4310507","NIHMS577268","10.1111/rssc.12067"
"23597282","In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities","Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.","AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23. doi: 10.1089/aid.2012.0385. Epub 2013 Jun 25.","Janes H","AIDS Res Hum Retroviruses","2013","2013/04/20","PMC3809388","","10.1089/aid.2012.0385"
"33191955","A Hybrid Approach for the Stratified Mark-Specific Proportional Hazards Model with Missing Covariates and Missing Marks, with Application to Vaccine Efficacy Trials","Sun Y, Qi L, Heng F, Gilbert PB.","J R Stat Soc Ser C Appl Stat. 2020 Aug;69(4):791-814. doi: 10.1111/rssc.12417. Epub 2020 May 22.","Sun Y","J R Stat Soc Ser C Appl Stat","2020","2020/11/16","PMC7664296","NIHMS1643050","10.1111/rssc.12417"
"15737083","Two-sample tests for comparing intra-individual genetic sequence diversity between populations","Gilbert PB, Rossini AJ, Shankarappa R.","Biometrics. 2005 Mar;61(1):106-17. doi: 10.1111/j.0006-341X.2005.020719.x.","Gilbert PB","Biometrics","2005","2005/03/02","","","10.1111/j.0006-341X.2005.020719.x"
"20072667","Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development","Huang Y, Gilbert PB, Montefiori DC, Self SG.","Stat Biopharm Res. 2009 Feb 1;1(1):81-91. doi: 10.1198/sbr.2009.0008.","Huang Y","Stat Biopharm Res","2009","2010/01/15","PMC2805400","NIHMS152082","10.1198/sbr.2009.0008"
"16107949","HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine","Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M.","J Infect Dis. 2005 Sep 15;192(6):974-83. doi: 10.1086/432734. Epub 2005 Aug 12.","Gilbert PB","J Infect Dis","2005","2005/08/19","","","10.1086/432734"
"23181167","A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens","Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.","Stat Commun Infect Dis. 2011 Oct;3(1):1037. doi: 10.2202/1948-4690.1037.","Gilbert PB","Stat Commun Infect Dis","2011","2012/11/28","PMC3502884","NIHMS356973","10.2202/1948-4690.1037"
"20419758","Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts","Gilbert PB.","Stat Med. 2010 May 10;29(10):1061-71. doi: 10.1002/sim.3676.","Gilbert PB","Stat Med","2010","2010/04/27","PMC2929839","NIHMS149454","10.1002/sim.3676"
"16789816","On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials","Wick WD, Gilbert PB, Self SG.","PLoS Comput Biol. 2006 Jun 16;2(6):e64. doi: 10.1371/journal.pcbi.0020064. Epub 2006 Jun 16.","Wick WD","PLoS Comput Biol","2006","2006/06/23","PMC1479086","","10.1371/journal.pcbi.0020064"
"19838313","PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS","Sun Y, Gilbert PB, McKeague IW.","Ann Stat. 2009 Feb 1;37(1):394-426. doi: 10.1214/07-AOS554.","Sun Y","Ann Stat","2009","2009/10/20","PMC2762218","NIHMS93879","10.1214/07-AOS554"
"25648332","Calibration weighted estimation of semiparametric transformation models for two-phase sampling","Fong Y, Gilbert P.","Stat Med. 2015 May 10;34(10):1695-707. doi: 10.1002/sim.6439. Epub 2015 Feb 4.","Fong Y","Stat Med","2015","2015/02/05","PMC4390487","NIHMS662842","10.1002/sim.6439"
"15831584","Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation","Gilbert PB, Sun Y.","Biostatistics. 2005 Jul;6(3):374-94. doi: 10.1093/biostatistics/kxi014. Epub 2005 Apr 14.","Gilbert PB","Biostatistics","2005","2005/04/16","","","10.1093/biostatistics/kxi014"
"17608781","Genome scanning tests for comparing amino acid sequences between groups","Gilbert PB, Wu C, Jobes DV.","Biometrics. 2008 Mar;64(1):198-207. doi: 10.1111/j.1541-0420.2007.00845.x. Epub 2007 Jun 30.","Gilbert PB","Biometrics","2008","2007/07/05","","","10.1111/j.1541-0420.2007.00845.x"
"15130048","Tests for comparing mark-specific hazards and cumulative incidence functions","Gilbert PB, McKeague IW, Sun Y.","Lifetime Data Anal. 2004 Mar;10(1):5-28. doi: 10.1023/b:lida.0000019253.69537.91.","Gilbert PB","Lifetime Data Anal","2004","2004/05/08","","","10.1023/b:lida.0000019253.69537.91"
